Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis

Frontiers in Medicine(2023)10.3389/fmed.2023.1167806Source: DataRank Database

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis is a research paper published in Frontiers in Medicine (2023). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.18)OA: goldTopics (36)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Anatoly Urisman ORCID,Onur Çil ORCID,Sanober Sadiq

Live enrichment

PubMed:37206472 PMC:PMC10189804 OpenAlex:https://openalex.org/W4368376594

NIDDK NIH HHS

Grant: R01 DK126070

National Institutes of Health

Grant: 5P30DK072517-02

CORE--CLINICAL RESOURCES

National Institutes of Health

Grant: 5R01DK126070-05

SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and Nephrolithiasis

FWCI

0.18

Citation Percentile

0.4%

Citation Trend

2024

2026

goldLicense: cc-by

journalhttps://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1167806/pdf

publisherhttps://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1167806/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fmed.2023.1167806/full

journalhttp://dx.doi.org/10.3389/fmed.2023.1167806

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37206472

Fields of Study

Complement system in diseasesBlood groups and transfusionImmunodeficiency and Autoimmune Disorders

Keywords

EculizumabAtypical hemolytic uremic syndromeMedicineDiscontinuationImmunologyThrombotic microangiopathyEtiologyGlomerulonephritisPediatricsInternal medicineComplement systemAntibodyDiseaseKidneyPrognosisFusobacteriumAtypical HusEikenellaEculizumab DiscontinuationMedicine (General)Kidney DiseasePreventionInflammatory and immune system610Autoimmune Disease618Rare DiseasesGood Health and Well BeingR5-920Clinical Research5.1 PharmaceuticalsGeneticsDevelopment of treatments and therapeutic interventions

Sustainable Development Goals

SDG 0: Good health and well-being